Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Reshape Lifesciences Inc (NQ: RSLS )

0.1684 +0.0014 (+0.84%)
Streaming Delayed Price Updated: 12:16 PM EDT, May 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Reshape Lifesciences Inc

< Previous 1 2 3 Next >
ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
Conference Call to be Held at 4:30 pm ET on Wednesday, May 15, 2024 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System
Patent Significantly Strengthens Intellectual Property Portfolio 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX
First Time Introduction of Lap-Band® 2.0 FLEX to the Next Generation of Surgeons 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update
Conference Call to be Held at 5:00 pm ET on Wednesday, November 8, 2023 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System
Royalty-Bearing License Agreement Covers the Countries in the Indian Subcontinent, Representing Approximately 20% to 25% of the World’s Population 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System
Granted One Patent from USPTO and Receives Two Notices of Allowance, Providing Foundational Protection 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device
$331,541 Grant will Explore the use of High-Resolution Endoscopic Ultrasound to Aid in the Placement of the DBSN™ Device 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Reports Second Quarter Ended June 30, 2023 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2023 and Provide Corporate Update
Conference Call to be Held at 5:00 pm ET on Monday, August 7, 2023 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software
Hive’s AI- and SMS-based Patient-Self-Service Technology to Manage Prospective Lap-Band® Leads From Initial Contact Through Surgical Consultation 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the ASMBS 2023 Annual Meeting
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0
Enhanced Band Reservoir Technology Designed to Improve the Patient Experience 
From ReShape Lifesciences Inc
Via GlobeNewswire
Life Science Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Life Science Investor Forum Agenda Announced for June 22nd
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
ReShape Lifesciences® to Participate in Investor and Industry Conferences in June
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Reports First Quarter Ended March 31, 2023 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2023 and Provide Corporate Update
Conference Call to be Held at 4:30 pm ET on Monday, May 15, 2023 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® to Present Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the Keystone Symposia on Type 2 Diabetes
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Reports Year Ended December 31, 2022 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to its Obalon® Balloon System
From ReShape Lifesciences Inc
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.